<code id='D7F3D3C3D5'></code><style id='D7F3D3C3D5'></style>
    • <acronym id='D7F3D3C3D5'></acronym>
      <center id='D7F3D3C3D5'><center id='D7F3D3C3D5'><tfoot id='D7F3D3C3D5'></tfoot></center><abbr id='D7F3D3C3D5'><dir id='D7F3D3C3D5'><tfoot id='D7F3D3C3D5'></tfoot><noframes id='D7F3D3C3D5'>

    • <optgroup id='D7F3D3C3D5'><strike id='D7F3D3C3D5'><sup id='D7F3D3C3D5'></sup></strike><code id='D7F3D3C3D5'></code></optgroup>
        1. <b id='D7F3D3C3D5'><label id='D7F3D3C3D5'><select id='D7F3D3C3D5'><dt id='D7F3D3C3D5'><span id='D7F3D3C3D5'></span></dt></select></label></b><u id='D7F3D3C3D5'></u>
          <i id='D7F3D3C3D5'><strike id='D7F3D3C3D5'><tt id='D7F3D3C3D5'><pre id='D7F3D3C3D5'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:328
          Anna Yeo/STAT

          Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

          In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way. 

          advertisement

          Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

          focus

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

          CarstenSnejbjerg/BloombergLONDON—TheinvestmentarmofNovoNordisk’sparentfoundationisbuyingdrugmanufact

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          The CDC's new social media misinformation war

          KIRILLKUDRYAVTSEV/AFP/GettyImagesYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewslet